SCHEMBL29566944

SCHEMBL29566944

Cc1ccccc1-c1nc(NS(=O)(=O)c2cnn(C)c2)nc(Oc2cccc(N3CCN(C)CC3)c2Cl)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 5/20 0.36
▸ HTR7 P34969 4/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ HTR6 P50406 6/20 0.34
▸ DRD2 P14416 4/20 0.34
▸ DRD4 P21917 3/20 0.34
▸ HTR2A P28223 3/20 0.34
▸ EGFR P00533 2/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ ADRA2A P08913 2/20 0.34
▸ DRD1 P21728 2/20 0.34
▸ DRD5 P21918 2/20 0.34
▸ BRD4 O60885 2/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAP3K7 O43318 1/20 0.33
▸ MAP2K1 Q02750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26808935 1.00 HTR1A (0.36) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL24310703 0.95 HTR1A (0.36) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL29566582 0.95 HTR1A (0.36) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL26808707 0.94 HTR6 (0.37) HTR1AHTR7HTR6DRD2DRD4
SCHEMBL24310708 0.93 HTR1A (0.35) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL29566915 0.93 HTR1A (0.35) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL24310080 0.93 HTR1A (0.36) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL29567132 0.93 HTR1A (0.36) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL24310556 0.92 HTR1A (0.36) HTR1AHTR7NPC1HTR6DRD2
SCHEMBL29566268 0.92 HTR1A (0.36) HTR1AHTR7NPC1HTR6DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback